Search results
Showing 16 to 30 of 163 results for copd
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235
In development [GID-TA11246] Expected publication date: TBC
This indicator covers the percentage of patients with COPD and Medical Research Council (MRC) Dyspnoea Scale of 3 or more at any time in the preceding 15 months, with a subsequent record of an offer of referral to a pulmonary rehabilitation programme. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM47
This indicator covers the percentage of patients with COPD on the register, who have had a review in the preceding 12 months, including a record of the number of exacerbations and an assessment of breathlessness using the Medical Research Council dyspnoea scale. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM170
This indicator covers the percentage of patients with very severe chronic obstructive pulmonary disease (COPD) with a record of oxygen saturation value within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM194
This indicator covers the percentage of patients with COPD who have had influenza immunisation in the preceding 1 August to 31 March. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM106
This indicator covers the proportion of people with chronic obstructive pulmonary disease (COPD) and Medical Research Council (MRC) dyspnoea scale 3 and above who are referred to a pulmonary rehabilitation programme. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG08.
This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.
myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)
NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .
NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .
Endobronchial nerve ablation for chronic obstructive pulmonary disease (IPG714)
Evidence-based recommendations endobronchial nerve ablation for chronic obstructive pulmonary disease. This involves destroying (ablating) the nerves on the outside of the airway (endobronchial nerves) to improve breathing.
View recommendations for IPG714Show all sections
Find out about the progress made by the health and care system in implementing NICE guidance on respiratory conditions
Awaiting development [GID-MT608] Expected publication date: TBC
Recommendation ID NG115/3 Question Inhaled therapies for people with COPD and asthma- What is the clinical and cost effectiveness of...
NG115/6 Question Diagnosing COPD: - What are the characteristics of people diagnosed with COPD as a result of an...
All NICE products on chronic obstructive pulmonary disease. Includes any guidance, advice and quality standards.